N700S VWF multimer analysis in young survivors of MI
. | MI patients . | . | Controls . | . | . | ||
|---|---|---|---|---|---|---|---|
. | S700 . | N700 . | S700 . | N700 . | P* . | ||
| No. of patients | 17 | 9 | 9 | 9 | NA | ||
| HMW % (95% CI) | 31.2 (29.1-33.3) | 28.7 (25.0-32.4) | 31.1 (27.1-35.0) | 29.9 (25.8-33.9) | .20 | ||
| CBA/Ag (95% CI) | 1.0 (0.9-1.0) | 1.0 (0.9-1.2) | 1.0 (0.8-1.1) | 1.0 (0.9-1.2) | .20 | ||
. | MI patients . | . | Controls . | . | . | ||
|---|---|---|---|---|---|---|---|
. | S700 . | N700 . | S700 . | N700 . | P* . | ||
| No. of patients | 17 | 9 | 9 | 9 | NA | ||
| HMW % (95% CI) | 31.2 (29.1-33.3) | 28.7 (25.0-32.4) | 31.1 (27.1-35.0) | 29.9 (25.8-33.9) | .20 | ||
| CBA/Ag (95% CI) | 1.0 (0.9-1.0) | 1.0 (0.9-1.2) | 1.0 (0.8-1.1) | 1.0 (0.9-1.2) | .20 | ||
HMW indicates percentage of high-molecular-weight VWF multimers measured by densitometry; CBA/Ag, collagen-binding activity relative to VWF antigen concentration; NA, not applicable.
S700 versus N700.